Pulse Biosciences reported a third-quarter loss of $0.32 per share, beating the -$0.35 consensus by 8.6%. Revenue of $0.4 million missed the $0.5 million estimate by 21.0%. Neither number is what moves this stock. The quarter's defining event was clinical: the NANOPULSE-AF U.S. pivotal IDE study for the nPulse cardiac catheter completed enrollment in under six months. That was three months ahead of the original plan, and it finished above the amended target with 169 evaluable patients. The central tension is that execution on the U.S. path accelerated while the European timeline slipped, the spending outlook rose, and the share count kept climbing to pay for it all.

The EPS beat deserves scrutiny. On a GAAP basis, the net loss widened to $23.1 million from $19.4 million a year ago, and earnings fell 10.3% year over year. The non-GAAP net loss grew to $17.5 million from $13.5 million. Research and development jumped to $16.8 million from $11.4 million on clinical program and headcount spending, partly offset by lower SG&A and stock compensation. A weighted share count of 71.9 million, up from 67.4 million, also spread the loss more thinly. Revenue grew 359.3% year over year, but that comparison is against an essentially pre-commercial base. Sequentially, Vybrance revenue of $395,000 was down from $434,000 in Q2 and roughly flat with Q1's $401,000. The company still describes the launch as controlled and expects this phase to run into Q4 2027. One bright spot within the tiny revenue line: cost of revenue fell to $191,000 from $273,000 in Q2.

The balance sheet changed most. Cash, equivalents and marketable securities nearly doubled to $189.2 million from $101.6 million, driven by $95.8 million in Q3 at-the-market proceeds. Pulse has raised more than $150 million since May, which management characterized as less than 6% dilution. Management pegs runway at roughly two years, and interest income now runs above $7.5 million annually. Operating cash burn fell to $15.3 million from $18.7 million in Q2, though the call indicated part of that improvement was timing. That cushion will be needed. Management now guides quarterly non-GAAP operating expenses 15% to 25% above the roughly $20 million average, a reversal from the Q2 guide to stay within that range. About $64 million of ATM capacity remains, so further dilution is a live possibility.

The call shifted in tone from enrollment execution to commercial scale-up. Management highlighted a second contract manufacturer, a senior catheter-manufacturing hire, and U.S. launch readiness targeted for early 2028. Final blended six- and 12-month pivotal data are expected in Q3 2027. Other catalysts on the calendar:

• a persistent AF IDE submission in Q4 2026;
• a European update covering more than 100 patients at 12 months, slated for early 2027;
• first-in-human testing of a next-generation focal/circumferential catheter in 2027;
• preliminary PRECISE-BTN thyroid data showing 86% of patients achieving more than 50% nodule volume reduction with no serious adverse events, which management says supports a 510(k).

Bears have legitimate ammunition. Catheter CE mark approval is now guided to Q4 2027, versus mid-2027 on the Q1 and Q2 calls. There will be no interim IDE readout. Management declined to discuss IDE safety data when an analyst raised a hemolysis/acute kidney injury case from the feasibility study. Questions also persist about whether the U.S. population will mirror the European feasibility cohort. No strategic partnership has materialized, and the co-chair acknowledged that potential partners want more proof before paying the valuation Pulse is seeking.

The market setup is more complicated than the EPS beat implies. Shares entered the report at $57.06, up 50.8% from the $37.84 open after the August report. That left the stock just 3.1% below the $58.90 52-week high set on September 9, near the top of an inter-earnings range that bottomed at $37.40. Investor sentiment improved modestly, from 0.08 to 0.14, and remains only mildly positive despite the rally. The Earnings Whispers momentum and AVWAP trend readings are positive, while the price trend is neutral. That neutral reading fits a stock that has consolidated below its September peak rather than extending higher.

The bottom line is that Pulse delivered the de-risking milestone that matters most, early pivotal enrollment, and funded the road to data and launch. However, the stock already priced in much of that progress ahead of the report. Delayed CE timelines, rising spending, continued dilution, unanswered safety questions, and the absence of a partner give skeptics specific issues to watch while investors wait for 2027 data.